These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32984900)

  • 1. TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20.
    Al-Bogami M; Bystrom J; Clanchy F; Taher TE; Mangat P; Williams RO; Jawad AS; Mageed RA
    Rheumatology (Oxford); 2021 Feb; 60(2):947-957. PubMed ID: 32984900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical assessment of changes in bone density in rheumatoid arthritis patients': Role of DEXA scan and bone turnover biomarkers.
    Al-Bogami MM; Alkhorayef M; Sulieman A; Bradley D; Jawad AS; Mageed RA
    Appl Radiat Isot; 2024 Sep; 211():111373. PubMed ID: 38851075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study.
    Wheater G; Elshahaly M; Naraghi K; Tuck SP; Datta HK; van Laar JM
    PLoS One; 2018; 13(8):e0201527. PubMed ID: 30080871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy.
    Barnabe C; Hanley DA
    Semin Arthritis Rheum; 2009 Oct; 39(2):116-22. PubMed ID: 18585759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF
    Bystrom J; Clanchy FI; Taher TE; Al-Bogami MM; Muhammad HA; Alzabin S; Mangat P; Jawad AS; Williams RO; Mageed RA
    Clin Rev Allergy Immunol; 2017 Oct; 53(2):265-276. PubMed ID: 28488248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
    PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
    Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
    Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
    Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
    Gulyás K; Horváth Á; Végh E; Pusztai A; Szentpétery Á; Pethö Z; Váncsa A; Bodnár N; Csomor P; Hamar A; Bodoki L; Bhattoa HP; Juhász B; Nagy Z; Hodosi K; Karosi T; FitzGerald O; Szücs G; Szekanecz Z; Szamosi S; Szántó S
    Clin Rheumatol; 2020 Jan; 39(1):167-175. PubMed ID: 31522318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts.
    O' Gradaigh D; Ireland D; Bord S; Compston JE
    Ann Rheum Dis; 2004 Apr; 63(4):354-9. PubMed ID: 15020327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Koike T
    Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U; Teichmann J; Müller-Ladner U; Strunk J
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
    Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
    Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis.
    Gómez-Vaquero C; Martín I; Zacarías A; Alía P; Loza E; Carmona L; Narváez J
    Curr Rheumatol Rev; 2021; 17(1):101-108. PubMed ID: 33349216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
    Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
    Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.